Wende Hutton

General Partner at Canaan Partners · Joined 2004

View Live Interactive Profile →

Biography

Wende Hutton is a General Partner at Canaan, where her bio states she identifies, builds and invests in companies bringing novel drugs, technologies and devices to market. She joined Canaan in 2004 after starting her venture career as a General Partner at Mayfield and holding senior marketing roles at GenPharm and Nellcor. Canaan lists Antiva Biosciences, Glooko, Hyalex Orthopaedics and Qlaris Bio among her current investments, and Chimerix, Dermira, Labrys Biologics and Transcend Medical among her previous ones. She holds an A.B. in human biology from Stanford University and an M.B.A. from Harvard Business School.

Education

Previous Experience

Notable Investments

GlookoHyalex OrthopaedicsQlaris BioAntiva BiosciencesDermira

Board Seats

Career Timeline

2004
Joined Canaan as a General Partner on the West Coast.
2011
Named as a Canaan Partners participant in Dermira's $42 million Series A financing.
2015
Joined the Glooko board of directors as part of the company's $16.5 million Series B.
2017
Joined the Hyalex Orthopaedics board of directors alongside its $16 million Series A.
2024
Spoke for Canaan as General Partner on Qlaris Bio's $24 million Series B financing.

Sources & References

Canaan - Wende Hutton ↗Antiva Biosciences - Board of Directors ↗Glooko - $16.5M Series B press release ↗PR Newswire - Hyalex Orthopaedics $16M Series A ↗Qlaris Bio - $24M Series B ↗BioSpace - Dermira $42M Series A ↗Aspen Ideas - Wende Hutton speaker bio ↗